Iktos specializes in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design. Their deep learning generative models enable the design of molecules that meet the success criteria of small molecule discovery projects. Their technology offers major productivity gains in pharmaceutical R&D and is available as both professional services and a SaaS software platform. Iktos offers Makya™, a de novo drug design platform for multi-parametric optimization of lead compounds, and is also developing Spaya™, a synthesis planning software based on their proprietary AI technology. Their algorithm designs novel compounds that are easy to make and optimized to meet specific blueprints, with unprecedented speed, performance, and diversity.